Abstract
Objective: The high cost of orphan drugs limits their access by many patients, especially in low- and middle-income countries. Many orphan drugs are off-patent without alternative generic or biosimilar versions available. Production of these drugs at the point-of-care, when feasible, could be a cost-effective alternative.
Methods: The financial feasibility of this approach was estimated by setting up a small-scale production of recombinant human acid alpha-glucosidase (rhGAA). The commercial version of rhGAA is Myozyme™, and Lumizyme™ in the United States, which is used to treat Pompe disease. The rhGAA was produced in CHO-K1 mammalian cells and purified using multiple purification steps to obtain a protein profile comparable to Myozyme™.
Results: The established small-scale production of rhGAA was used to obtain a realistic cost estimation for the magistral production of this biological drug. The treatment cost of rhGAA using bedside production was estimated at $3,484/gram, which is 71% lower than the commercial price of Myozyme ™.
Conclusion: This study shows that bedside production might be a cost-effective approach to increase the access of patients to particular life-saving drugs.
Keywords: Affordability, bedside production, orphan drug, Pompe disease, rare disease, rhGAA.
Graphical Abstract
[http://dx.doi.org/10.5582/irdr.3.1] [PMID: 25343119]
[http://dx.doi.org/10.1186/s13167-016-0074-2] [PMID: 27980697]
[PMID: 21977136]
[http://dx.doi.org/10.1038/s41431-017-0008-z] [PMID: 29158551]
[http://dx.doi.org/10.1186/s13023-017-0617-1] [PMID: 28372595]
[http://dx.doi.org/10.1371/journal.pone.0140002] [PMID: 26451948]
[http://dx.doi.org/10.1016/j.healthpol.2017.09.005] [PMID: 29033060]
[http://dx.doi.org/10.1016/j.jval.2018.01.007] [PMID: 29753352]
[http://dx.doi.org/10.1016/j.csbj.2016.06.007] [PMID: 27570613]
[http://dx.doi.org/10.1038/nbt.3888] [PMID: 28581491]
[http://dx.doi.org/10.1097/01.gim.0000218152.87434.f3] [PMID: 16702877]
[http://dx.doi.org/10.1016/j.jpeds.2004.01.053] [PMID: 15126982]
[http://dx.doi.org/10.1042/bj2720485] [PMID: 2268275]
[http://dx.doi.org/10.1074/jbc.M404008200] [PMID: 15520017]
[http://dx.doi.org/10.1074/jbc.M112.438663] [PMID: 23188827]
[http://dx.doi.org/10.1016/j.ymgme.2008.04.009] [PMID: 18538603]
[http://dx.doi.org/10.1038/nbt0809-685a]
[http://dx.doi.org/10.1186/1750-1172-9-75] [PMID: 24884717]
[PMID: 24991376]
[http://dx.doi.org/10.1021/acs.analchem.5b00870] [PMID: 26192159]
[http://dx.doi.org/10.4161/mabs.2.5.12645] [PMID: 20647768]
[http://dx.doi.org/10.1016/j.chroma.2007.03.126] [PMID: 17449042]
[http://dx.doi.org/10.1016/S0021-9673(01)01275-4] [PMID: 11758747]
[http://dx.doi.org/10.1093/glycob/cws058] [PMID: 22369936]
[http://dx.doi.org/10.1093/glycob/cwv001] [PMID: 25573276]
[http://dx.doi.org/10.1186/1755-8417-1-6] [PMID: 19046416]
[http://dx.doi.org/10.2307/1906860]
[http://dx.doi.org/10.2165/11584230-000000000-00000] [PMID: 21142275]
[PMID: 9352080]
[http://dx.doi.org/10.1111/cts.12500] [PMID: 28796445]
[http://dx.doi.org/10.1517/21678707.2013.819289]